Sharps Technology (NASDAQ:STSS – Get Free Report) is one of 234 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its peers? We will compare Sharps Technology to related businesses based on the strength of its earnings, institutional ownership, analyst recommendations, profitability, valuation, risk and dividends.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Sharps Technology and its peers, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Sharps Technology | 0 | 0 | 0 | 0 | N/A |
Sharps Technology Competitors | 1705 | 4504 | 8676 | 235 | 2.49 |
As a group, “Surgical & medical instruments” companies have a potential upside of 25.32%. Given Sharps Technology’s peers higher possible upside, analysts clearly believe Sharps Technology has less favorable growth aspects than its peers.
Insider and Institutional Ownership
17.2% of Sharps Technology shares are held by institutional investors. Comparatively, 48.2% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 12.6% of Sharps Technology shares are held by company insiders. Comparatively, 15.4% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Sharps Technology and its peers gross revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Sharps Technology | N/A | -$9.84 million | -0.44 |
Sharps Technology Competitors | $1.03 billion | $3.51 million | -4,694.91 |
Sharps Technology’s peers have higher revenue and earnings than Sharps Technology. Sharps Technology is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Sharps Technology and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Sharps Technology | N/A | -102.25% | -72.97% |
Sharps Technology Competitors | -673.57% | -130.38% | -27.83% |
Volatility and Risk
Sharps Technology has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Sharps Technology’s peers have a beta of 0.98, meaning that their average share price is 2% less volatile than the S&P 500.
Summary
Sharps Technology peers beat Sharps Technology on 6 of the 10 factors compared.
About Sharps Technology
Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
Receive News & Ratings for Sharps Technology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sharps Technology and related companies with MarketBeat.com’s FREE daily email newsletter.